Announcements and Notices - [Other - Business Update]

Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.

Voluntary Announcement-Semaglutide Injection Developed By Huisheng Biopharmaceutical For Weight Loss Indication Obtained Ind Approval From Nmpa

Announcements and Notices - [Dividend or Distribution (Announcement Form)]

Interim Cash Dividend For The Six Months Ended 30 June 2024

Announcements and Notices - [Interim Results / Dividend or Distribution / Closure of Books or Change of Book Closure Period]

Announcement Of Interim Results For The Six Months Ended 30 June 2024

Announcements and Notices - [Date of Board Meeting]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sihuan Pharmaceutical Hldgs (460 HK)

Voluntary Announcement-Semaglutide Injection Developed By Huisheng Biopharmaceutical For Weight Loss Indication Obtained Ind Approval From Nmpa

Interim Cash Dividend For The Six Months Ended 30 June 2024

Announcement Of Interim Results For The Six Months Ended 30 June 2024

Notice Of Board Meeting

Voluntary Announcement-Insulin Degludec Injection Huiyouda Developed By Huisheng Biopharmaceutical Obtained Drug Registration Approval From Nmpa

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)